Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface pol… Read more
Kane Biotech Inc (KNBIF) - Total Liabilities
Latest total liabilities as of September 2024: $4.59 Million USD
Based on the latest financial reports, Kane Biotech Inc (KNBIF) has total liabilities worth $4.59 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kane Biotech Inc - Total Liabilities Trend (2014–2022)
This chart illustrates how Kane Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kane Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Kane Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eonmetall Group Bhd
KLSE:7217
|
Malaysia | RM196.95 Million |
|
Nitiraj Engineers Limited
NSE:NITIRAJ
|
India | ₹99.72 Million |
|
Pilot Energy Ltd
AU:PGY
|
Australia | AU$27.40 Million |
|
Gyrodyne Company of America Inc
NASDAQ:GYRO
|
USA | $27.77 Trillion |
|
Methanor
PA:ALMET
|
France | €35.87K |
|
Pacific Ridge Exploration Ltd
OTCQB:PEXZF
|
USA | $389.75K |
|
Seko S.A.
WAR:SEK
|
Poland | zł39.60 Million |
|
Kun Peng International Ltd.
OTCQB:KPEA
|
USA | $9.03 Million |
Liability Composition Analysis (2014–2022)
This chart breaks down Kane Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kane Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kane Biotech Inc (2014–2022)
The table below shows the annual total liabilities of Kane Biotech Inc from 2014 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $9.76 Million | +26.70% |
| 2021-12-31 | $7.70 Million | +94.43% |
| 2020-12-31 | $3.96 Million | +106.42% |
| 2019-12-31 | $1.92 Million | -24.48% |
| 2018-12-31 | $2.54 Million | +285.53% |
| 2017-12-31 | $659.03K | -15.91% |
| 2016-12-31 | $783.72K | +13.11% |
| 2015-12-31 | $692.86K | +12380.20% |
| 2014-12-31 | $5.55K | -- |